MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 562798 | Name: Rhosin
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Rhosin is an inhibitor of RhoA and RhoC interaction with GEFs. It acts by preventing RhoA activation and downstream MLC phosphorylation, filamentous actin formation and focal adhesion assembly without perturbing endogenous Cdc42 or Rac signalling.

Chemical Structure

Rhosin
Rhosin
CAS#1173671-63-0

Theoretical Analysis

MedKoo Cat#: 562798

Name: Rhosin

CAS#: 1173671-63-0

Chemical Formula: C20H18N6O

Exact Mass: 358.1542

Molecular Weight: 358.41

Elemental Analysis: C, 67.02; H, 5.06; N, 23.45; O, 4.46

Price and Availability

Size Price Availability Quantity
25mg USD 500.00
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Rhosin; G04; G-04; G 04;
IUPAC/Chemical Name
(2R)-2-amino-3-(2,3-dihydro-1H-inden-1-yl)-N'-((E)-quinolin-7-ylmethylene)propanehydrazide
InChi Key
FGYHLIHEFHCMPP-FVWOBLMASA-N
InChi Code
InChI=1S/C20H18N6O/c21-16(10-14-12-24-17-4-2-1-3-15(14)17)20(27)26-25-11-13-5-6-18-19(9-13)23-8-7-22-18/h1-9,11-12,16,24H,10,21H2,(H,26,27)/b25-11+/t16-/m1/s1
SMILES Code
O=C([C@@H](CC1=CNC2=C1C=CC=C2)N)N/N=C/C3=CC=C4N=CC=NC4=C3
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Rhosin binds to RhoA to inhibit RhoA-GEF interaction with a Kd of ~ 0.4 uM. It does not interact with Cdc42 or Rac1, nor the GEF, LARG. Rhosin induces cell apoptosis. Rhosin promotes stress resiliency through enhancing D1-MSN plasticity and reducing hyperexcitability.
In vitro activity:
Rhosin inhibited tumor cell adhesion to the extracellular matrix via suppression of RHAMM expression, and inhibited SDF-1-induced cell migration and invasion by decreasing CXCR4 expression in B16BL6 and 4T1 cells. These results suggest that rhosin’s inhibition of RhoA/C-YAP pathway has potential as a therapeutic approach in patients with melanoma and breast cancer. Reference: Biomedicines. 2021 Jan 4;9(1):35. https://pubmed.ncbi.nlm.nih.gov/33406809/
In vivo activity:
When 25 μM of Y16 and 25 μM of Rhosin were combined, the inhibitory effect on LARG-RhoA interaction was statistically significant. When Y16 and Rhosin were combined, a significantly reduced concentration could effectively inhibit MYPT1 phosphorylation (2.5 μM compared with 5 μM for Y16 alone). Reference: J Formos Med Assoc. 2021 Oct;120(10):1863-1868. https://pubmed.ncbi.nlm.nih.gov/33893012/
Solvent mg/mL mM
Solubility
DMSO 3.6 10.00
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 358.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Chiu WC, Chiang JY, Chiang FT. Small chemical compounds Y16 and Rhosin can inhibit calcium sensitization pathway in vascular smooth muscle cells of spontaneously hypertensive rats. J Formos Med Assoc. 2021 Oct;120(10):1863-1868. doi: 10.1016/j.jfma.2021.03.031. Epub 2021 Apr 21. PMID: 33893012. 2. Tsubaki M, Genno S, Takeda T, Matsuda T, Kimura N, Yamashita Y, Morii Y, Shimomura K, Nishida S. Rhosin Suppressed Tumor Cell Metastasis through Inhibition of Rho/YAP Pathway and Expression of RHAMM and CXCR4 in Melanoma and Breast Cancer Cells. Biomedicines. 2021 Jan 4;9(1):35. doi: 10.3390/biomedicines9010035. PMID: 33406809; PMCID: PMC7824767. 3. Chiu WC, Chiang JY, Chiang FT. Small chemical compounds Y16 and Rhosin can inhibit calcium sensitization pathway in vascular smooth muscle cells of spontaneously hypertensive rats. J Formos Med Assoc. 2021 Oct;120(10):1863-1868. doi: 10.1016/j.jfma.2021.03.031. Epub 2021 Apr 21. PMID: 33893012.
In vitro protocol:
1. Chiu WC, Chiang JY, Chiang FT. Small chemical compounds Y16 and Rhosin can inhibit calcium sensitization pathway in vascular smooth muscle cells of spontaneously hypertensive rats. J Formos Med Assoc. 2021 Oct;120(10):1863-1868. doi: 10.1016/j.jfma.2021.03.031. Epub 2021 Apr 21. PMID: 33893012. 2. Tsubaki M, Genno S, Takeda T, Matsuda T, Kimura N, Yamashita Y, Morii Y, Shimomura K, Nishida S. Rhosin Suppressed Tumor Cell Metastasis through Inhibition of Rho/YAP Pathway and Expression of RHAMM and CXCR4 in Melanoma and Breast Cancer Cells. Biomedicines. 2021 Jan 4;9(1):35. doi: 10.3390/biomedicines9010035. PMID: 33406809; PMCID: PMC7824767.
In vivo protocol:
1. Chiu WC, Chiang JY, Chiang FT. Small chemical compounds Y16 and Rhosin can inhibit calcium sensitization pathway in vascular smooth muscle cells of spontaneously hypertensive rats. J Formos Med Assoc. 2021 Oct;120(10):1863-1868. doi: 10.1016/j.jfma.2021.03.031. Epub 2021 Apr 21. PMID: 33893012.
1: Oblinger JL, Wang J, Wetherell GD, Agarwal G, Wilson TA, Benson NR, Fenger JM, Fuchs JR, Kinghorn AD, Chang LS. Anti-tumor effects of the eIF4A inhibitor didesmethylrocaglamide and its derivatives in human and canine osteosarcomas. Sci Rep. 2024 Aug 20;14(1):19349. doi: 10.1038/s41598-024-69171-3. PMID: 39164287; PMCID: PMC11335891. 2: Oblinger J, Wang J, Wetherell G, Agarwal G, Wilson T, Benson N, Fenger J, Fuchs J, Kinghorn AD, Chang L. Anti-tumor Effects of the eIF4A Inhibitor Didesmethylrocaglamide and Its Derivatives in Human and Canine Osteosarcomas. Res Sq [Preprint]. 2024 Jun 14:rs.3.rs-4494024. doi: 10.21203/rs.3.rs-4494024/v1. Update in: Sci Rep. 2024 Aug 20;14(1):19349. doi: 10.1038/s41598-024-69171-3. PMID: 38947012; PMCID: PMC11213195. 3: Medica S, Crawford LB, Denton M, Min CK, Jones TA, Alexander T, Parkins CJ, Diggins NL, Streblow GJ, Mayo AT, Kreklywich CN, Smith P, Jeng S, McWeeney S, Hancock MH, Yurochko A, Cohen MS, Caposio P, Streblow DN. Proximity-dependent mapping of the HCMV US28 interactome identifies RhoGEF signaling as a requirement for efficient viral reactivation. PLoS Pathog. 2023 Oct 2;19(10):e1011682. doi: 10.1371/journal.ppat.1011682. PMID: 37782657; PMCID: PMC10569644. 4: Yamada S, Yassin MA, Torelli F, Hansmann J, Green JBA, Schwarz T, Mustafa K. Unique osteogenic profile of bone marrow stem cells stimulated in perfusion bioreactor is Rho-ROCK-mediated contractility dependent. Bioeng Transl Med. 2023 Mar 17;8(3):e10509. doi: 10.1002/btm2.10509. PMID: 37206242; PMCID: PMC10189446. 5: Li L, Xin J, Wang H, Wang Y, Peng W, Sun N, Huang H, Zhou Y, Liu X, Lin Y, Fang J, Jing B, Pan K, Zeng Y, Zeng D, Qin X, Bai Y, Ni X. Fluoride disrupts intestinal epithelial tight junction integrity through intracellular calcium- mediated RhoA/ROCK signaling and myosin light chain kinase. Ecotoxicol Environ Saf. 2023 Jun 1;257:114940. doi: 10.1016/j.ecoenv.2023.114940. Epub 2023 Apr 24. PMID: 37099960. 6: Dandamudi A, Seibel W, Tourdot B, Cancelas JA, Akbar H, Zheng Y. Structure- Activity Relationship Analysis of Rhosin, a RhoA GTPase Inhibitor, Reveals a New Class of Antiplatelet Agents. Int J Mol Sci. 2023 Feb 19;24(4):4167. doi: 10.3390/ijms24044167. PMID: 36835579; PMCID: PMC9961652. 7: Beak M, Park S, Kim JH, Eom HJ, Lee HY, Kim YH, Lee J, Nam S. Second- Generation JK-206 Targets the Oncogenic Signal Mediator RHOA in Gastric Cancer. Cancers (Basel). 2022 Mar 22;14(7):1604. doi: 10.3390/cancers14071604. PMID: 35406376; PMCID: PMC8997135. 8: Liu H, Zeng X, Ma Y, Chen X, Losiewicz MD, Du X, Tian Z, Zhang S, Shi L, Zhang H, Yang F. Long-term exposure to low concentrations of MC-LR induces blood-testis barrier damage through the RhoA/ROCK pathway. Ecotoxicol Environ Saf. 2022 May 1;236:113454. doi: 10.1016/j.ecoenv.2022.113454. Epub 2022 Mar 31. PMID: 35367887. 9: Zhang D, Zhu Y, Li Z, Luo M, Liang X, Wang A, Zhu H, Hu L, Li R. The role of Astragalus polysaccharides in promoting IEC-6 cell migration from polyamine- mediated Ca2+ regulation. Int J Biol Macromol. 2022 May 15;207:179-192. doi: 10.1016/j.ijbiomac.2022.02.109. Epub 2022 Feb 23. PMID: 35217086. 10: Somodi L, Beke Debreceni I, Kis G, Cozzolino M, Kappelmayer J, Antal M, Panyi G, Bárdos H, Mutch NJ, Muszbek L. Activation mechanism dependent surface exposure of cellular factor XIII on activated platelets and platelet microparticles. J Thromb Haemost. 2022 May;20(5):1223-1235. doi: 10.1111/jth.15668. Epub 2022 Feb 21. PMID: 35146910; PMCID: PMC9303193. 11: Shivangi, Meena LS. A multifactorial assessment of the SRP pathway constituent FtsY as a vital mycobacterial constituent. Biotechnol Appl Biochem. 2022 Dec;69(6):2445-2453. doi: 10.1002/bab.2294. Epub 2022 Jan 8. PMID: 34837716. 12: Okamoto Y, Kitakaze K, Takenouchi Y, Yamamoto S, Ishimaru H, Tsuboi K. Sphingosine 1-phosphate receptor type 2 positively regulates interleukin (IL)-4/IL-13-induced STAT6 phosphorylation. Cell Signal. 2021 Dec;88:110156. doi: 10.1016/j.cellsig.2021.110156. Epub 2021 Sep 28. PMID: 34592416. 13: Sundberg M, Pinson H, Smith RS, Winden KD, Venugopal P, Tai DJC, Gusella JF, Talkowski ME, Walsh CA, Tegmark M, Sahin M. 16p11.2 deletion is associated with hyperactivation of human iPSC-derived dopaminergic neuron networks and is rescued by RHOA inhibition in vitro. Nat Commun. 2021 May 18;12(1):2897. doi: 10.1038/s41467-021-23113-z. PMID: 34006844; PMCID: PMC8131375. 14: Chiu WC, Chiang JY, Chiang FT. Small chemical compounds Y16 and Rhosin can inhibit calcium sensitization pathway in vascular smooth muscle cells of spontaneously hypertensive rats. J Formos Med Assoc. 2021 Oct;120(10):1863-1868. doi: 10.1016/j.jfma.2021.03.031. Epub 2021 Apr 21. PMID: 33893012. 15: Devi SS, Yadav R, Arya R. Altered Actin Dynamics in Cell Migration of GNE Mutant Cells. Front Cell Dev Biol. 2021 Mar 18;9:603742. doi: 10.3389/fcell.2021.603742. PMID: 33816461; PMCID: PMC8012676. 16: Tsubaki M, Genno S, Takeda T, Matsuda T, Kimura N, Yamashita Y, Morii Y, Shimomura K, Nishida S. Rhosin Suppressed Tumor Cell Metastasis through Inhibition of Rho/YAP Pathway and Expression of RHAMM and CXCR4 in Melanoma and Breast Cancer Cells. Biomedicines. 2021 Jan 4;9(1):35. doi: 10.3390/biomedicines9010035. PMID: 33406809; PMCID: PMC7824767. 17: Ariyani W, Miyazaki W, Amano I, Hanamura K, Shirao T, Koibuchi N. Soy Isoflavones Accelerate Glial Cell Migration via GPER-Mediated Signal Transduction Pathway. Front Endocrinol (Lausanne). 2020 Nov 4;11:554941. doi: 10.3389/fendo.2020.554941. PMID: 33250856; PMCID: PMC7672195. 18: Privat M, Cavard A, Zekri Y, Ponelle-Chachuat F, Molnar I, Sonnier N, Bignon YJ. A high expression ratio of RhoA/RhoB is associated with the migratory and invasive properties of basal-like Breast Tumors. Int J Med Sci. 2020 Oct 1;17(17):2799-2808. doi: 10.7150/ijms.43101. PMID: 33162807; PMCID: PMC7645338. 19: Abramochkin DV, Filatova TS, Pustovit KB, Dzhumaniiazova I, Karpushev AV. Small G-protein RhoA is a potential inhibitor of cardiac fast sodium current. J Physiol Biochem. 2021 Feb;77(1):13-23. doi: 10.1007/s13105-020-00774-w. Epub 2020 Nov 4. PMID: 33145656. 20: Kim JH, Park S, Lim SM, Eom HJ, Balch C, Lee J, Kim GJ, Jeong JH, Nam S, Kim YH. Rational design of small molecule RHOA inhibitors for gastric cancer. Pharmacogenomics J. 2020 Aug;20(4):601-612. doi: 10.1038/s41397-020-0153-6. Epub 2020 Feb 4. PMID: 32015453.